Evolutionary analysis of indeterminate cytology and risk of malignancy in a thyroid nodule unit.

Ana Isabel Alvarez-Mancha, Isabel Mancha-Doblas, María Molina-Vega, Diego Fernández-García, Ana María Gómez-Pérez, Elena Gallego, María Victoria Ortega-Jiménez, Isabel Hierro-Martín, Francisco J Tinahones
Author Information
  1. Ana Isabel Alvarez-Mancha: A Alvarez-Mancha, Department of Medicine, University of Malaga, 29010 Malaga, Spain. b, University of Malaga, Malaga, Spain.
  2. Isabel Mancha-Doblas: I Mancha-Doblas, Department of Medicine, University of Malaga, 29010 Malaga, Spain. , University of Malaga, Malaga, Spain.
  3. María Molina-Vega: M Molina-Vega, Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, 29010 Málaga, Spain, University Hospital Virgen de la Victoria, Malaga, Spain.
  4. Diego Fernández-García: D Fernández-García, Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, 29010 Málaga, Spain, University Hospital Virgen de la Victoria, Malaga, Spain.
  5. Ana María Gómez-Pérez: A Gómez-Pérez, Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, 29010 Málaga, Spain, University Hospital Virgen de la Victoria, Malaga, Spain.
  6. Elena Gallego: E Gallego, Department of Medicine, University of Malaga, 29010 Malaga, Spain, University of Malaga, Malaga, Spain.
  7. María Victoria Ortega-Jiménez: M Ortega-Jiménez , Department of Medicine, University of Malaga, 29010 Malaga, Spain, University of Malaga, Malaga, Spain.
  8. Isabel Hierro-Martín: I Hierro-Martín, Department of Pathology, Virgen de la Victoria University Hospital, University Hospital Virgen de la Victoria, Malaga, Spain.
  9. Francisco J Tinahones: F Tinahones, Department of Medicine, University of Malaga, 29010 Malaga, Spain, University of Malaga, Malaga, Spain.

Abstract

OBJECTIVE: The objective of this study was to analyze the evolution in the diagnosis and management of indeterminate thyroid nodules over three time periods.
METHODS: 3020 patients with thyroid nodules underwent cytological evaluation during three periods (2006-2008, 2012-2014, 2017-2019). Distribution of diagnostic cytologies, risk of malignancy, diagnostic performance indices of FNA, and cytologic-histologic correlation in indeterminate cytologies were analyzed.
RESULTS: only 2.2% of cytology tests were insufficient for a diagnosis. 86.9% cytologies were benign, 1.7% malignant, and 11.4% indeterminate. Indeterminate cytology rates were 15.9% (2006-2008), 10.1% (2012-2014), and 10% (2017-2019). Surgery was performed in 13% of benign cytology, result-ing in malignant histology in 2.7%. All malignant and suspicious cytologies underwent surgery: malig-nancy confirmed in 98% and 77% of cases, respectively. All 'indeterminate with atypia' cytologies (2006-2008) and Bethesda IV (2012-2014; 2017-2019) un-derwent surgery, with malignancy confirmed in 19.6%, 43.8%, and 25.7%, respectively. In the 'inde-terminate without atypia' category (2006-2008) and Bethesda III (2012-2014; 2017-2019), diagnostic surgery was performed in 57.7%, 78.6%, and 59.4%, respectively, with malignancy confirmed in 3.3%, 20.5%, and 31.6%. The FNA sensitivity was 91.6% with a negative predictive value greater than 96% in all periods. The specificity exceeded 75% in the last two periods.
CONCLUSION: Bethesda system reduces indeterminate cytologies and improves the accuracy of FNA diagnosis. We reported a higher proportion of malignancy than expected in Bethesda III, underscoring the importance of having institution-specific data to guide decision-making. However, there is a need for risk stratification tools that allow for conservative management in low-risk cases.

References

  1. Int J Mol Sci. 2023 May 05;24(9): [PMID: 37176002]
  2. Acta Cytol. 2016;60(5):399-405 [PMID: 27764825]
  3. Diagn Cytopathol. 2017 Feb;45(2):113-117 [PMID: 28024119]
  4. Endocr Relat Cancer. 2021 Apr;28(4):225-235 [PMID: 33640868]
  5. Korean J Radiol. 2015 Mar-Apr;16(2):391-401 [PMID: 25741201]
  6. Surgery. 2015 Mar;157(3):510-7 [PMID: 25633738]
  7. Int J Endocrinol. 2020 Apr 14;2020:7325260 [PMID: 32351561]
  8. Thyroid. 2009 Nov;19(11):1167-214 [PMID: 19860577]
  9. Endocr Pract. 2016 May;22(5):622-39 [PMID: 27167915]
  10. Clin Endocrinol (Oxf). 2012 Jul;77(1):13-7 [PMID: 22469035]
  11. BMJ. 2020 Jan 7;368:l6670 [PMID: 31911452]
  12. Eur J Endocrinol. 2021 Aug 27;185(4):497-506 [PMID: 34313606]
  13. Diagn Cytopathol. 2018 Feb;46(2):148-153 [PMID: 29193839]
  14. Cancer. 2007 Oct 25;111(5):306-15 [PMID: 17680588]
  15. Endocr J. 2014;61(6):539-52 [PMID: 24727657]
  16. Diagn Cytopathol. 2003 Oct;29(4):203-6 [PMID: 14506672]
  17. Endocrine. 2017 Feb;55(2):530-538 [PMID: 27075721]
  18. Endocr Pract. 2006 Jan-Feb;12(1):63-102 [PMID: 16596732]
  19. Endocrine. 2017 Aug;57(2):256-261 [PMID: 27804016]
  20. Ultrasonography. 2023 Apr;42(2):307-313 [PMID: 36935593]
  21. Diagn Cytopathol. 2008 Feb;36(2):104-12 [PMID: 18181183]
  22. J Clin Endocrinol Metab. 2008 Nov;93(11):4175-82 [PMID: 18987277]
  23. Cytojournal. 2006 Apr 07;3:9 [PMID: 16603062]
  24. Endocrinol Nutr. 2011 Oct;58(8):409-15 [PMID: 21930441]
  25. Clin Endocrinol (Oxf). 2016 Aug;85(2):275-82 [PMID: 26639612]
  26. Thyroid. 2018 Aug;28(8):1004-1012 [PMID: 29848195]
  27. Eur Thyroid J. 2023 Aug 14;12(5): [PMID: 37358008]
  28. Cancer Cytopathol. 2023 Jul;131(7):415-420 [PMID: 36973997]
  29. Diagn Cytopathol. 2022 May;50(5):223-229 [PMID: 35133716]
  30. Eur J Endocrinol. 2006 Jun;154(6):787-803 [PMID: 16728537]
  31. Thyroid. 2006 Feb;16(2):109-42 [PMID: 16420177]
  32. Thyroid. 2023 Sep;33(9):1039-1044 [PMID: 37427847]
  33. Medicine (Baltimore). 2017 Apr;96(16):e6564 [PMID: 28422844]
  34. J Clin Endocrinol Metab. 2009 May;94(5):1748-51 [PMID: 19276237]
  35. Thyroid. 2014 Jul;24(7):1115-20 [PMID: 24684285]
  36. BMC Res Notes. 2008 May 15;1:12 [PMID: 18710537]
  37. Diagn Cytopathol. 2020 Dec;48(12):1237-1243 [PMID: 32716614]
  38. Am J Clin Pathol. 2011 Oct;136(4):572-7 [PMID: 21917679]
  39. Clin Endocrinol (Oxf). 2014 Jul;81 Suppl 1:1-122 [PMID: 24989897]
  40. Am J Clin Pathol. 2008 Nov;130(5):736-44 [PMID: 18854266]
  41. Clin Endocrinol (Oxf). 2017 Apr;86(4):584-590 [PMID: 27911001]
  42. Thyroid. 2017 Nov;27(11):1341-1346 [PMID: 29091573]
  43. J Clin Endocrinol Metab. 2020 Sep 1;105(9): [PMID: 32491169]
  44. Eur Thyroid J. 2017 Sep;6(5):225-237 [PMID: 29167761]
  45. Am J Clin Pathol. 2009 Nov;132(5):658-65 [PMID: 19846805]
  46. BMC Endocr Disord. 2019 Oct 29;19(1):112 [PMID: 31664992]
  47. Cancer Cytopathol. 2021 Dec;129(12):966-972 [PMID: 34399035]
  48. Ultrasonography. 2023 Oct;42(4):600-601 [PMID: 37691418]
  49. Front Endocrinol (Lausanne). 2020 Feb 18;11:53 [PMID: 32132976]
  50. Thyroid. 2016 Jan;26(1):1-133 [PMID: 26462967]
  51. Korean J Radiol. 2016 May-Jun;17(3):370-95 [PMID: 27134526]
  52. Cancer Cytopathol. 2020 Apr;128(4):238-249 [PMID: 31883438]
  53. Endocr Pract. 2010 May-Jun;16(3):468-75 [PMID: 20551008]
  54. J Am Coll Radiol. 2017 May;14(5):587-595 [PMID: 28372962]

Word Cloud

Created with Highcharts 10.0.0cytologiesindeterminatemalignancyperiods2006-20082012-20142017-2019cytology7%Bethesda6%diagnosisthyroiddiagnosticriskFNAmalignantconfirmedrespectivelymanagementnodulesthreeunderwent29%benign4%performedcasesatypia'surgeryIIIOBJECTIVE:objectivestudyanalyzeevolutiontimeMETHODS:3020patientscytologicalevaluationDistributionperformanceindicescytologic-histologiccorrelationanalyzedRESULTS:2%testsinsufficient86111Indeterminaterates15101%10%Surgery13%result-inghistologysuspicioussurgery:malig-nancy98%77%'indeterminateIVun-derwent19438%25'inde-terminatewithoutcategory57785933%205%31sensitivity91negativepredictivevaluegreater96%specificityexceeded75%lasttwoCONCLUSION:systemreducesimprovesaccuracyreportedhigherproportionexpectedunderscoringimportanceinstitution-specificdataguidedecision-makingHoweverneedstratificationtoolsallowconservativelow-riskEvolutionaryanalysisnoduleunit

Similar Articles

Cited By